Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-08-02
2011-08-02
Angell, Jon E (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S04400A
Reexamination Certificate
active
07989428
ABSTRACT:
A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a gemcitabine and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with gemcitabine alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects.
REFERENCES:
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 5583016 (1996-12-01), Villeponteau et al.
patent: 5629154 (1997-05-01), Kim et al.
patent: 5891639 (1999-04-01), Harley et al.
patent: 5952490 (1999-09-01), Hanecak et al.
patent: 6261836 (2001-07-01), Cech et al.
patent: 6331399 (2001-12-01), Monia et al.
patent: 6444650 (2002-09-01), Cech et al.
patent: 6548298 (2003-04-01), Villeponteau et al.
patent: 6608036 (2003-08-01), Gryaznov et al.
patent: 6995145 (2006-02-01), Au et al.
patent: 7067497 (2006-06-01), Hanecak et al.
patent: 7485717 (2009-02-01), Gryaznov et al.
patent: 7494982 (2009-02-01), Gryaznov et al.
patent: 2006/0128651 (2006-06-01), Au et al.
patent: 2007/0015723 (2007-01-01), Hanecak et al.
patent: 2007/0270363 (2007-11-01), Bennett et al.
patent: 2010/0010064 (2010-01-01), Moore et al.
patent: 2010/0104586 (2010-04-01), Tressler et al.
patent: WO-98/28442 (1998-07-01), None
patent: WO-2005/000245 (2005-01-01), None
patent: WO-2006/113426 (2006-10-01), None
patent: WO-2006/113470 (2006-10-01), None
patent: WO-2006/124904 (2006-11-01), None
patent: WO-2008/112129 (2008-09-01), None
Asai, A. et al., “A Novel Telomerase Template Antagonist (GRN163) as a Potential Anticancer Agent,”Cancer Res. 63(2003), pp. 3931-3939.
Blackburn, E., “Telomerases,”Annu. Rev. Biochem. 61 (1992), pp. 113-129.
Chen, J. et al., “Secondary structure of vertebrate telomerase RNA,”Cell100 (2000), pp. 503-514.
Gryaznov, S. et al., “Oligonucleotide N3′->P5′ thiophosphoramidate telomerase template antagonists as potential anticancer agents,”Nucleosides, Nucleotides&Nucl. Acids 22(5-8) (2003), pp. 577-581.
Harley, C., “Telomere loss: Mitotic clock or genetic time bomb?”Mutation. Res. 256(1991), pp. 271-282.
Herbert, B-S. et al., “Oligonucleotide N3′->P5′ phosphoramidates as efficient telomerase inhibitors,”Oncogene 21(4) (2002), pp. 638-642.
Kim, M. et al., “A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation,”Proc. Natl. Acad. Sci. USA 98(14) (2001), pp. 7982-7987.
Kraemer, K. et al., “Chemosensitization of bladder cancer cell lines by human telomerase reverse transcriptase antisense treatment,”J. Urology 172(5 Pt. 1) (2004), pp. 2023-2028.
Kupihar, Z. et al., “Synthesis and application of a novel, crystalline phosphoramidite monomer with thiol terminus, suitable for the synthesis of DNA conjugates,”Bioorg. Med. Chem. 9(5) (2001), pp. 1241-1247.
Lebedeva, I. et al., “Antisense oligonucleotides: promise and reality,”Annu. Rev. Pharmacol. Toxicol. 41(2001), pp. 403-419.
Macejak, D. et al., “Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo,”J. Virol. 73(9) (1999), pp. 7745-7751.
McCurdy, S. et al., “An Improved Method for the Synthesis of N3′->P5′ Phosphoramidate Oligonucleotides,”Tetrahedron Lett. 38(2) (1997), pp. 207-210.
Mishra, R. et al., “Improved leishmanicidal effect of phosphorotioate antisense oligonucleotides by LDL-mediated delivery,”Biochim. Biophys. Acta 1264(2) (1995), pp. 229-237.
Nelson, J S. et al., “N3′-P5′ oligodeoxyribonucleotide phosphoramidates: a new method of synthesis based on a phosphoramidate amine-exchange reaction,”J. Org. Chem. 62(1997), pp. 7278-7287.
Pongracz, K. et al., “Oligonucleotide N3′—>P5′ thiophosphoramidates: synthesis and properties,”Tetrahedron Lett. 40(1999), pp. 7661-7664.
Pruzan, R. et al., “Allosteric inhibitors of telomerase: oligonucleotide N3′—>P5′ phosporamidates,”Nucl. Acids Res. 30(21 (2002), pp. 559-568.
Rump, E. et al., “Preparation of conjugates of oligodeoxynucleotides and lipid structures and their interaction with low-density lipoprotein,”Bioconjugate Chem. 9(1998), pp. 341-349.
Shea, R. et al., “Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates,”Nucl. Acids Res. 18(13) (1990), pp. 3777-3783.
Zeng, Y. et al., “MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms,”Proc. Natl. Acad. Sci. USA 100(17) (2003), pp. 9779-9784.
PCT Search Report for PCT/US2007/022850, mailed Sep. 30, 2008, 1 page.
Supplementary European Search Report and European Search Opinion for Appl. No. EP 07867297.9, dated Oct. 11, 2011, 7 pages.
Go, N. et al., “Single agent and combination treatment studies with the telomerase inhibitor GRN163L in ovarian cancer and non-small cell lung carcinoma (NSCLC) xenograft models”,Eur. J. Cancer4(Suppl. 12) (2006), p. 189, Abstract.
Hochreiter, A. et al., “Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer”,Clin. Cancer Res. 12(10) (2006), pp. 3184-3192.
Senkal, C. et al., “Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo”,J. Pharmacol. Exp. Ther. 317(3) (2006), pp. 1188-1199.
Univ. Liverpool Clinical Trial, “A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination gemcitabine and capecitabine therapy with concurrent and sequential chemoimmunotherapy using a telomerase vaccine in locally advanced and metastatic pancreatic cancer”ISRCTN43482138(2005) 3 pages.
Go Ning F.
Tressler Robert J.
Angell Jon E
Geron Corporation
Mooi Leslie A.
LandOfFree
Combined telomerase inhibitor and gemcitabine for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined telomerase inhibitor and gemcitabine for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined telomerase inhibitor and gemcitabine for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2619329